Literature DB >> 21454390

Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum--implications for therapeutic targets to prevent encapsulating peritoneal sclerosis.

Niko Braun1, Peter Fritz, Dagmar Biegger, Martin Kimmel, Fabian Reimold, Christoph Ulmer, M Dominik Alscher.   

Abstract

OBJECTIVE: Encapsulating peritoneal sclerosis (EPS) is a rare but life-threatening complication of peritoneal dialysis (PD). The optimal management of patients with EPS is uncertain. In the present study, we investigated differences in the expression of nuclear receptors [progesterone (PR), androgen (AR), vitamin D (VDR), and glucocorticoid (GCR)] in the human peritoneum. We also investigated estrogen receptor (ER), matrix metalloproteinase 9 (MMP9), and transforming growth factor β1 (TGFβ1) in the context of their potential role in tamoxifen therapy.
METHODS: We analyzed clinical and histologic characteristics of 72 peritoneal biopsy specimens (22 from EPS patients, 11 from PD patients, 15 from uremic patients, and 24 from control subjects undergoing hernia repair). For immunophenotyping, we used antibodies against VDR, GCR, ER, PR, AR, MMP9, and TGFβ1.
RESULTS: In human peritoneum, VDR and GCR are highly expressed (98.6% and 87.3% respectively). Except in the case of VDR (p = 0.0012), we observed no significant difference in receptor expression between the groups. Expression of ER and PR was sparse (11.4% and 31% respectively), with higher expression in women, and AR was absent. Minimal MMP9 expression and moderate TGFβ1 expression were observed in all groups. The differences between the groups were nonsignificant.
CONCLUSIONS: Nuclear receptors are present in human peritoneum. Except in the case of VDR, the pattern for any one group is nonspecific. Glucocorticoids, vitamin D, and angiotensin converting-enzyme inhibitors or angiotensin II receptor blockers (via the vitamin D/angiotensin II pathway) might be suitable interventions for preservation of the integrity of the peritoneal membrane. The mechanism of action of tamoxifen is still not elucidated, ER expression in the peritoneum is sparse, and data about the studied pathways (MMP9, TGFβ) are inconsistent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454390     DOI: 10.3747/pdi.2010.00118

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  10 in total

1.  Gadolinium deposits could influence the course of encapsulating peritoneal sclerosis.

Authors:  Joerg Latus; Eric Goffin; Josef A Schroeder; Peter Fritz; German Ott; Christoph Ulmer; Wolfgang Steurer; Martin Kimmel; Dagmar Biegger; Stephan Segerer; M Dominik Alscher; Niko Braun
Journal:  Perit Dial Int       Date:  2014 Jul-Aug       Impact factor: 1.756

Review 2.  Pharmacologic targets and peritoneal membrane remodeling.

Authors:  Karima Farhat; Andrea W D Stavenuiter; Rob H J Beelen; Piet M Ter Wee
Journal:  Perit Dial Int       Date:  2014 Jan-Feb       Impact factor: 1.756

3.  22-Oxacalcitriol prevents progression of peritoneal fibrosis in a mouse model.

Authors:  Misaki Hirose; Tomoya Nishino; Yoko Obata; Masayuki Nakazawa; Yuka Nakazawa; Akira Furusu; Katsushige Abe; Masanobu Miyazaki; Takehiko Koji; Shigeru Kohno
Journal:  Perit Dial Int       Date:  2012-10-02       Impact factor: 1.756

4.  Phenotypes of encapsulating peritoneal sclerosis--macroscopic appearance, histologic findings, and outcome.

Authors:  Joerg Latus; Christoph Ulmer; Peter Fritz; Bianka Rettenmaier; Dagmar Biegger; Thomas Lang; German Ott; Martin Kimmel; Wolfgang Steurer; M Dominik Alscher; Stephan Segerer; Niko Braun
Journal:  Perit Dial Int       Date:  2013-02-01       Impact factor: 1.756

Review 5.  Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review.

Authors:  Roberto Russo; Marinella Ruospo; Mario Cozzolino; Luca De Nicola; Andrea Icardi; Ernesto Paoletti; Sandro Mazzaferro
Journal:  J Nephrol       Date:  2014-07-11       Impact factor: 3.902

6.  Encapsulating peritoneal sclerosis: surgery, sustained drug therapy and treatment of recurrence at 1 year.

Authors:  Robin Cho; Danielle Ghag; Mohamud Amirali Karim; Clifford Lo
Journal:  BMJ Case Rep       Date:  2015-11-11

7.  Transcriptional patterns in peritoneal tissue of encapsulating peritoneal sclerosis, a complication of chronic peritoneal dialysis.

Authors:  Fabian R Reimold; Niko Braun; Zsuzsanna K Zsengellér; Isaac E Stillman; S Ananth Karumanchi; Hakan R Toka; Joerg Latus; Peter Fritz; Dagmar Biegger; Stephan Segerer; M Dominik Alscher; Manoj K Bhasin; Seth L Alper
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

Review 8.  The local inflammatory responses to infection of the peritoneal cavity in humans: their regulation by cytokines, macrophages, and other leukocytes.

Authors:  Marien Willem Johan Adriaan Fieren
Journal:  Mediators Inflamm       Date:  2012-02-26       Impact factor: 4.711

9.  Targeting lysyl oxidase reduces peritoneal fibrosis.

Authors:  Christopher R Harlow; Xuan Wu; Marielle van Deemter; Fiona Gardiner; Craig Poland; Rebecca Green; Sana Sarvi; Pamela Brown; Karl E Kadler; Yinhui Lu; J Ian Mason; Hilary O D Critchley; Stephen G Hillier
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

10.  1,25-Dihydroxyvitamin D3 Prevents Epithelial-Mesenchymal Transition of HMrSV5 Human Peritoneal Mesothelial Cells by Inhibiting Histone Deacetylase 3 (HDAC3) and Increasing Vitamin D Receptor (VDR) Expression Through the Wnt/β-Catenin Signaling Pathway.

Authors:  Kang-Han Liu; Jia Fu; Nan Zhou; Wei Yin; Yi-Ya Yang; Sha-Xi Ouyang; Yu-Mei Liang
Journal:  Med Sci Monit       Date:  2019-08-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.